申请人:ADIR et Compagnie
公开号:US04782054A1
公开(公告)日:1988-11-01
Morpholine compounds of the formula: ##STR1## in which R.sub.1 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, (C.sub.5 -C.sub.6)-cycloalkyl or (C.sub.2 -C.sub.6)-acyl; and R.sub.2 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, or (C.sub.2 -C.sub.3)-acyl; enantiomers and physiologically tolerable acid salts thereof. These compounds may be used therapeutically especially in the treatment of ischaemic syndromes and of cerebral ageing.
化学式为:##STR1## 的吗啡啶化合物,其中R.sub.1为氢,直链或支链(C.sub.1-C.sub.6)-烷基,可能含有双键,芳基烷基可能被取代,(C.sub.5-C.sub.6)-环烷基或(C.sub.2-C.sub.6)-酰基; R.sub.2为氢,直链或支链(C.sub.1-C.sub.6)-烷基,可能含有双键,芳基烷基可能被取代,或(C.sub.2-C.sub.3)-酰基; 其对映体和生理耐受性酸盐。这些化合物可用于治疗缺血综合症和脑衰老等疾病。